1. Home
  2. AYTU vs EVGN Comparison

AYTU vs EVGN Comparison

Compare AYTU & EVGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • AYTU
  • EVGN
  • Stock Information
  • Founded
  • AYTU N/A
  • EVGN 1999
  • Country
  • AYTU United States
  • EVGN Israel
  • Employees
  • AYTU N/A
  • EVGN N/A
  • Industry
  • AYTU Biotechnology: Pharmaceutical Preparations
  • EVGN Agricultural Chemicals
  • Sector
  • AYTU Health Care
  • EVGN Industrials
  • Exchange
  • AYTU Nasdaq
  • EVGN Nasdaq
  • Market Cap
  • AYTU 10.7M
  • EVGN 9.7M
  • IPO Year
  • AYTU N/A
  • EVGN N/A
  • Fundamental
  • Price
  • AYTU $1.51
  • EVGN $1.60
  • Analyst Decision
  • AYTU
  • EVGN Strong Buy
  • Analyst Count
  • AYTU 0
  • EVGN 1
  • Target Price
  • AYTU N/A
  • EVGN $12.00
  • AVG Volume (30 Days)
  • AYTU 45.2K
  • EVGN 805.5K
  • Earning Date
  • AYTU 11-13-2024
  • EVGN 11-21-2024
  • Dividend Yield
  • AYTU N/A
  • EVGN N/A
  • EPS Growth
  • AYTU N/A
  • EVGN N/A
  • EPS
  • AYTU N/A
  • EVGN N/A
  • Revenue
  • AYTU $79,759,000.00
  • EVGN $7,478,000.00
  • Revenue This Year
  • AYTU N/A
  • EVGN $173.12
  • Revenue Next Year
  • AYTU $2.35
  • EVGN $33.10
  • P/E Ratio
  • AYTU N/A
  • EVGN N/A
  • Revenue Growth
  • AYTU N/A
  • EVGN 290.29
  • 52 Week Low
  • AYTU $1.41
  • EVGN $1.44
  • 52 Week High
  • AYTU $3.45
  • EVGN $10.40
  • Technical
  • Relative Strength Index (RSI)
  • AYTU 26.32
  • EVGN 29.49
  • Support Level
  • AYTU $1.41
  • EVGN $1.66
  • Resistance Level
  • AYTU $1.63
  • EVGN $1.78
  • Average True Range (ATR)
  • AYTU 0.21
  • EVGN 0.15
  • MACD
  • AYTU -0.01
  • EVGN -0.01
  • Stochastic Oscillator
  • AYTU 11.98
  • EVGN 20.00

About AYTU Aytu BioPharma Inc.

Aytu BioPharma Inc is a specialty pharmaceutical company with a commercial portfolio of prescription therapeutics and consumer health products. The company's primary prescription products treat attention deficit hyperactivity disorder and other common pediatric conditions. It is building a complementary therapeutic development pipeline including a prospective treatment (AR101/enzastaurin) for vascular Ehlers-Danlos Syndrome, a rare genetic disease resulting in high morbidity and a significantly shortened lifespan. The company operates in two segments Rx Segment, consisting of prescription pharmaceutical products and Consumer Health segments of which the company generates maximum revenue from the Rx segment.

About EVGN Evogene Ltd

Evogene Ltd is a computational biology company targeting to revolutionize product development for life-science based industries, including human health, agriculture, and industrial applications. The company established its technology, the Computational Predictive Biology (CPB) platform. The CPB platform is designed to computationally discover and develop life-science products based on microbes, small molecules and genetic elements as the core components for such products. It holds a number of subsidiaries utilizing the CPB platform, for the development of human microbiome-based therapeutics, medical cannabis, ag-biologicals, ag-chemicals, seed traits and ag-solutions for castor oil production. It generates maximum revenue from the Agriculture segment followed by Industry.

Share on Social Networks: